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Abstract
Background: Community pharmacists’ (CPs’) interventions have a positive impact on managing respiratory patients.
However, methods used by CPs to assess patients’ inhaler technique and adherence are subjective. New technologies
to objectively assess inhaler technique and adherence were introduced to address such a gap. This study aimed to
explore CPs’ perceptions towards the management of respiratory patients regarding inhaler technique and adherence.
In addition, it explored the views of CPs and their need of technologies to objectively assess inhaler technique and
adherence. CPs were probed with a new technology called Inhaler Compliance Assessment (INCA) device, designed to
objectively monitor both inhaler technique and adherence of patients using a dry powder inhaler, as an example.
Methods: A qualitative study employing semi-structured interviews was conducted. A convenience and snowballing
sampling strategy was employed to recruit CPs working in independent community pharmacies within West and
South London. Twenty-three pharmacists were interviewed between August and November 2015. Data was analysed
thematically using the framework methodology and coded using NVivo10 software.
Results: Analysis revealed five main themes: services and limitations of patient support, the need and acceptability of
new technologies to support respiratory patients, fragmented primary care, the need to promote the clinical role of
CPs, and professional identity. Patient support was patchy and affected by several barriers related to pharmacists and
patients. In addition, lack of communications with different healthcare professionals in primary care and inaccessibility
to clinical records were identified as problematic issues. Some CPs perceived their clinical role to be lacking within the
patient care pathway. Interestingly, CPs showed positive a attitude towards the use of technologies, such as the INCA
technology to support patients and were willing to provide new services. However, remuneration appeared to be a
major driver for willingness to offer new services or promote existing services.
Conclusion: The current study highlighted some measures that can augment CPs’ clinical practice while managing
patients, such as having accessibility to patients’ medical records and the use of technologies such as the INCA
technology to promote objective counselling of patients.
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Background
Respiratory conditions such as asthma and chronic ob-
structive pulmonary disease (COPD) are examples of
long-term conditions (LTCs) that have a high economic
burden on the healthcare systems worldwide [1–5]. In-
haler therapy represents the backbone for the manage-
ment of these respiratory conditions [1, 6]. However,
poor adherence to inhaled medications and poor inhaler
technique have been repeatedly identified to be problem-
atic issues [1, 7–13]. Community pharmacists (CPs) are
well placed to provide services to patients with chronic
respiratory conditions [1, 12, 14–16]. In the UK, CPs
offer a range of services to promote medicine optimisa-
tion in patients with LTCs, such as: the Medicine Use
Review (MUR) service which is an adherence/concord-
ance review, with respiratory patients as target group
and the New Medicine Service (NMS) targeting patients
who are newly prescribed a medication for a LTC [17].
Several studies highlighted the positive impact of CPs’
interventions in optimising inhaler technique and adher-
ence for respiratory patients [18]. However, one of the
limitations of the current practice is the use of subjective
measures for assessing inhaler technique and adherence
[10, 19, 20] . The current standard for inhaler technique
assessment is a checklist method which varies between
studies [1, 21] and has been reported to be subjective
[22]. Strategies used to assess adherence were mainly by
self-reporting (questionnaires) or using medication refill
rate which in essence does not assess actual medication-
taking behaviour [23]. Therefore, assistive technologies to
objectively assess inhaler technique and adherence have
emerged to address such a gap. However, some of these
technologies assess adherence alone through recording the
date and time of actuations only, such as: the Neubilizer
Chronolog (NC), Smart Inhaler Tracker, SmartTrack, and
SmartTouch AV [24]. Whereas, others assess inhaler tech-
nique alone, such as the Aerosol Inhalation Monitor (AIM)
device [25] and Inhalation Manager (IM) [26]. One of the
most recent technologies in this domain is the Inhaler
Compliance Assessment (INCATM) device. The INCA™ de-
vice (Fig. 1) is a novel monitoring device that has the ad-
vantage of being an automatic and objective measure of
both inhaler technique and adherence at the same time
while patients using the inhaler at home [19, 20, 27]. The
device is manufactured by Vitalograph Ltd. [28]. It is a
small acoustic, battery operated device that can be attached
to the dry powder inhaler (DPI) without interfering with
the mechanism of drug delivery nor the mechanics of the
inhaler use [20, 22]. It provides objective feedback in the
form of graphical data showing the patient’s adherence
(date and time) and inhaler technique (indicating the most
common error type). The feedback generated can serve as
a guide for healthcare professionals (HCPs) to manage pa-
tients, especially those who are receiving an appropriate
medication regime but showing no improvement in their
condition [20].
The diffusion of such new technologies into practice
requires certain pre-requisites and processes to ensure
successful adoption and implementation. Rogers Diffu-
sion of Innovation (DOI) [29] theory describes the
process experienced by individuals or units in a social
system when a new idea/innovation is presented to
them. The characteristics of the innovation itself are par-
ticularly important in determining its rate of adoption.
Fig. 1 The INCA™ device attached to a Diskus dry powder inhaler (DPI)Permission to reproduce the figure of INCA™ device was granted from
Vitalograph Ltd. (28)
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According to the theory, the following attributes are es-
sential to facilitate the adoption of any innovation: rela-
tive advantage (the extent an innovation is perceived to
be better than the current available options/practices),
complexity (the degree of difficulty of an innovation in
terms of understanding and usage), compatibility (the
degree of consistency of an innovation with the already
existing values, beliefs, experiences and needs of the in-
dividuals/adopters), trialability (the extent to which an
innovation can be easily tried/experimented on a limited
basis before permanent adoption), observability (the
extent to which the innovation’s results/outcomes are
visible to others).
This study aimed to assess CPs’ perceptions, experi-
ences and current practice towards the management of
respiratory patients with respect to inhaler technique
and adherence. In addition, this study aimed to highlight
CPs’ perceptions and need for an objective measure of
inhaler technique and adherence, using INCATM tech-
nology as an example, given the increased recognition of
the impact that technologies can have on improving pa-
tients’ outcomes when incorporated in the wider pack-
age of care for patients [30].
Method
The research methods of this study are reported in accord-
ance to the Consolidated Criteria for Reporting Qualitative
Research (COREQ) [31] (See Additional file 1).
Study design
A qualitative approach using semi-structured interviews
was employed to address the aims of this study. The use
of semi-structured interviews was deemed suitable be-
cause it allowed for in-depth exploration of ideas, views
and experiences of CPs in relation to the investigated
topic. This method is underpinned by phenomenology
as a philosophical approach to obtain a detailed account
of the phenomena under investigation from the perspec-
tives of participants [32].
Study setting
The study was conducted within the following boroughs in
West and South London: Kingston upon Thames, Rich-
mond upon Thames, Hounslow, Merton, and Wandsworth.
Participants’ recruitment
A convenience sampling strategy, based on local know-
ledge and proximity to the researchers was used to re-
cruit participants. A list of independent community
pharmacies was identified by one researcher (IH)
through conducting a search on the National Health
Service (NHS) choices website for the contact details of
community pharmacies located within West and South
London. Multiple chain pharmacies were excluded due
to research governance requirements. CPs, owning or
working in independent community pharmacies within
West and South London, were approached in person by
the first author and provided with a written information
sheet about the study to consider. The researcher then
contacted the pharmacists by telephone or in person
and those who agreed to participate were included and a
schedule for the interview was determined. A snowbal-
ling technique [33] was also employed to identify add-
itional CPs to interview.
In qualitative research, there is no conventional guid-
ance to determine the sufficient sample size for inter-
views to be conducted [34, 35]. However, the concept of
data saturation has been widely used in many studies to
determine the sample size [34, 35]. Therefore, recruit-
ment was continued until data saturation was achieved,
where no new data was emerging out of the interviews.
The analysis process was cyclical and iterative which in-
volved the transcription and reading of the first few in-
terviews to achieve familiarisation with the data
collected and identify preliminary codes. After that, each
interview was transcribed and coded to help guide data
saturation. Data saturation was reached after the 20th
interview. The stopping criterion for data saturation,
which denotes the number of interviews conducted
without any new data after which recruitment can be
stopped, was three [36]. A total of 55 community phar-
macies were approached, and 23 CPs were successfully
recruited and interviewed. Most pharmacies declined
participation due to either staffing or time constraints.
Data collection
Semi-structured interviews were conducted face-to-face
by the first author, a female doctoral researcher who had
received training in conducting qualitative research in
healthcare settings. The interviews were conducted in
the private consultation room at the pharmacy to main-
tain confidentiality and avoid distraction. None of the
research team had relationships with any of the partici-
pants prior to study commencement. Therefore, a brief
introduction about the purpose of the research was pro-
vided by the interviewer prior to the interviews. Written
informed consent was also acquired before conducting
the interviews. Twenty-three CPs were interviewed be-
tween August and November 2015. The demographics
of the interviewees are summarised in Table (1). All in-
terviews were audio recorded and hand written notes
were taken during the interviews. The interviews lasted
between 20 and 35 min. No repeat interviews were con-
ducted with any of the participants.
The interview topic guide
The interview schedule (See Additional file 2) was devel-
oped by the research team to address the aims of the
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study and consisted of 17 open-ended questions that
covered the following sections: current practice related
to inhaler technique and adherence, confidence about
knowledge and services delivery, technology use within
current services, and barriers to provision of support to
respiratory patients. In the technology section, CPs were
probed with the INCA™ device as an example, since the
device is designed to objectively monitor both inhaler
technique and adherence at the same time, both of
which are reported in the literature to be problematic
among patients [1, 9–11, 13]. The first author showed
the CPs the INCATM device, a video on how to mount it
to the DPI, and the graphical output generated after the
analysis.
The interview schedule was piloted on 5 pharmacists
working within the same academic institution of the re-
search team and resulted in minor amendments.
Data analysis and reporting
The audio recorded interviews were transcribed verba-
tim, anonymised and analysed by the researcher who
conducted the interviews. Transcripts were not returned
to participants for comments. Data analysis was done
thematically by the first author based on the five-stage
framework approach [37–39]. The first stage involved
listening to the recorded data and reading and
re-reading a small number of interview transcripts and
any written notes to become familiar with the data. The
patterns within the responses in relation to CPs' experi-
ence of managing respiratory patients and the obstacles
they perceive to affect their role, together with their ex-
periences in using technology and its need to provide
objective monitoring of inhaler technique and adher-
ence, and the participants’ use of language while describ-
ing their experiences were examined. This enabled the
identification of the initial emergent codes.
The second stage involved the formation of the the-
matic framework to structure the analysis. The coding
framework was developed through a recursive process,
which was agreed by all researchers and involved
grouping of the initial codes and a priori literature re-
view into categories, which then formed the working
analytical framework. The broad categories identified
were: patients’ management and technology use. The
remaining transcripts were read and re-read to ensure
that all data had been coded and the analytical frame-
work was further developed as additional codes
emerged. Codes were then examined and grouped into
meaningful themes and subthemes where applicable.
Hence, derivation of themes was done using inductive/
deductive approaches. All themes were given an equal
weighting within the thematic framework. Numerical
Indexing was done to the developed framework by
assigning numbers to emergent themes and associated
subthemes, which was then applied to the transcribed
data. Charts were then created, which summarised the
respondents’ views and experiences within the emergent
themes and subthemes . This was followed by mapping
and interpretation of the data in relation to the research
objectives [37].
The transcripts were managed and coded using
NVivo10 software. The coded transcripts were continu-
ally and extensively discussed, and checked by the other
co-authors RK and SNG, which at times involved modi-
fication of the emergent themes. RK has a Doctor of
Philosophy (PhD) qualification and SNG has a Doctor of
Pharmacy (PharmD) qualification and both are female
university academics who have considerable experience
in conducting qualitative research. Agreement about all
the emerging themes and subthemes was verified by all
authors to ensure validity and consistency of the findings
and to overcome bias in data coding.
The results are presented in the form of themes and
subthemes. Participants’ quotes are used to substantiate
the findings presented under each theme. The theme re-
garding technology acceptability was interpreted using
the Rogers DOI theory [29].
Ethical consideration
The study received ethical approval from the Research
Ethics Committee at Kingston University London (Refer-
ence No. 1415/034).
Results
Analysis of the interviews revealed five main themes
(Table 2). Additional quotations to those presented
under each theme are available in Table 3.
Services and limitations of patient support
Services provided to respiratory patients
All CPs highlighted that they provide support to respira-
tory patients through services within the community
pharmacy contractual framework, mainly: dispensing, re-
peat dispensing, MUR, NMS, flu vaccination and smoking
Table 1 Demographic characteristics of study participants
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cessation. Supporting patients with inhaler technique and
adherence was mainly done during the MUR service
which is conducted once yearly if the patient accepts to
have the service, or opportunistically over the counter if
the patient raised a query.
“We do respiratory MURs as part of targeted MUR
group, we do NMS enhanced service for new patients
starting on a different inhaler whether asthma or
COPD, we also do flu vaccination and smoking
cessation.” (CP19).
Barriers to patient support
Several barriers were reported by CPs to affect support
and service provision to respiratory patients. Ten CPs
indicated providing MURs to respiratory patients every
two or three years and not on annual basis, because it
was difficult to get the same patient to do the MUR each
year, despite the fact that respiratory patients are a target
group for this service.
“MUR is an annual thing but it all depends that if we
get the patient again the following year so they may
have one off or it might be every two or three years, it
just depends on the catchment.” (CP12)
“…even just for the yearly MURs people are not willing
to take part and that is only once a year” (CP3)
Other barriers for services provision included: pharma-
cists’ time and workload, lack of training, lack of incen-
tives/re-imbursement, financial barriers, lack of resources
(placebo inhalers, manpower), patients’ time in addition to
patients’ health beliefs and attitudes.
“It is basically more about time, time regarding you are
busy dispensing medication, you do not have time unless
there is another pharmacist working at the same time.”
(CP4)
“A lot of people don’t want to do it (the MUR service),
not every year. Like I said before people’s attitudes and
people’s adherence is human nature, their beliefs.”
(CP3)
Therefore, patient support is patchy and opportunistic
depending on several factors related to either patients or
pharmacists.
Fragmented primary care
Lack of communication with other HCPs
The need and importance of collaboration between all
HCPs to promote care for respiratory patients was
clearly portrayed in CPs’ responses. Fragmented care
and lack of communication between HCPs were identi-
fied as main concern. According to CPs, patients cur-
rently tend to get services and information from
different HCPs without synchronisation and consistency;
this can lead to confusion among patients. The fragmen-
ted communication between HCPs means that CPs had
no clear idea about services offered to patients and,
therefore, their level of knowledge.
“I think the other thing which could be viewed as a
problem is the multiple approach from different parts
of the NHS …so you are having different things which
are not talking to each other...” (CP13)
One CP even highlighted their unsuccessful attempt to
promote a clear referral pathway between their service
and the general practitioners (GPs).
“You know I tried the surgeries, I spoke to all the
nurses and GPs and said if any patient comes to you,
you can get them come to me. I am quite happy I am
not going to charge anything and I will refer anybody
up to you if there are any issues. No one.” (CP11)
The use of the phrase ‘I am quite happy’ denoted that this
respondent was very keen to promote the management of
Table 2 Emergent themes and subthemes
Theme Subtheme (s)
Services and limitations of patient support Services provided to respiratory patients
Barriers to patient support
Fragmented primary care Lack of communication with other HCPs
Lack of access to patients’ records




The need to promote the clinical role of community pharmacists
Professional identity
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Table 3 additional quotations from respondents
Theme/ Subtheme Respondents’ Quotations
Theme 1: Services and Limitations of patient support
Subtheme: Services provided to
respiratory patients
“We do MURs or NMS for these patients…. We also do flu vaccination and smoking cessation.” (CP10)
“MURs, we are targeting respiratory MURs, smoking cessation my colleague does…. We do NMS… We do flu
vaccines at the moment” (CP13)
“Usually NMS and Smoking cessation service, MUR, flu vaccination.” (CP14)
Subtheme: Barriers to patient support “I think biggest barrier would be time, resources. It is basically, I think we need to think about rearranging our
time table so it would mean that we would have to have a little bit of extra resources, the only time I bring
people in the consultation room when I have a locum”. (CP6)
“Lack of training probably and again yea not having placebo inhalers, these two things” (CP7)
Patients’ attitudes and cooperation to have the service, the ability to recruit patients, the willingness to participate,
and the time we have to spend with patients (CP16).
“Time, because it can take 10–15 min each intervention especially when you want to check technique. Correct
reimbursement, because it comes out of our time. Barriers would be mainly time and reimbursement. If we got to
have tools supplied on a regular basis like my placebos go back to while ago so I have to keep asking the reps,
we do not see the reps any more so we don’t get placebos unless we ring the manufacturer.” (CP10)
Theme 2: Fragmented primary care
Subtheme: Lack of communication
with other HCPs
“And there is also I feel lack of information coming from the prescriber, for example: with the preventer steroid
inhalers they don’t say to them (the patients) use it regularly… so they (the patients) just use the reliever
whenever they need, and with the other one (preventer) they end up in trouble because they don’t realise it is far
better to manage.” (CP11)
“There is a bit of resistance from patients because they are saying we are repeating what the practice nurses may
have done. The practice nurse may have gone through all this with them and then they are wondering why is
the pharmacist doing it as well”.(CP17)
“…even we can’t access the GP surgery, communication is so bad, telephones are always busy, receptionists get
the doctor to call back…” (CP3)
Subtheme: Lack of access to patients’
records
“I think what is a barrier at the moment and what would help us and I think it is for the future, they are going to
allow us clinical access with our smart card for us to know so with our smart card not only we will be able to
look at the drug history of the patient but we should be able to look at the clinical history.” (CP4)
Theme 3: The need and acceptability of new technologies to support respiratory patients
Subtheme: Relative advantage “it shows they are using their device properly, using it on timely basis because unlike when I am talking to them, I
am trusting them to say yes I am using my inhaler. I am depending on the trust; I am using my inhaler twice a
day without fail. Whereas, this device would say you don’t use your device twice a day, you are telling me that
you use it. It allows us to actually say here you are to proof that sometimes you are not using the device properly,
sometimes you are not taking enough drug, sometimes you are missing it totally, you are not using it enough
etc…so yea I am for that technology” (CP12)
“yea definitely, I think it will be good for some patients because at least this way even doctors will be able to get
feedback about this. The information you are getting/creating here gets referred back essentially to a prescribing
body about usage and about the technique being used correctly. There is no point of prescribing something and
then not assessing the patients, there is a gap between usage and compliance and being used properly. I mean
you need to make sure the drug is being used effectively so then assess the patient thereafter so this information
should be good for the doctor to get back.”(CP18)
Subtheme: Compatibility “Sometimes it is easier with technology, isn’t it? It can make things easy for you.” (CP10)
“We see the information gathering from technology tends to be more useful so information gathering in old ways
tends to be difficult to actually utilise whereas it tends to be easier analysed with that technology to benefit the
patient. Easier to analyse and use.” (CP13)
Subtheme: Complexity “I mean as long as it is efficient, as long as it does not affect therapy then I will be happy to and as long as it is
easy to use.” (CP14)
“It has some beneficial factor (2b) and easy to use (2c). Going with the time. Sometimes it is easier, isn’t it? It can
make things easy for you.” (CP10)
Subtheme: Trialability and
observability
“By collecting preliminary data, if something new or new sort of advice come up that would bring benefit to the
patient so obviously yes.” (CP15)
“If I am offering something that I tried and I know works, they (patients) are advised that it works and if they use
it and find it works then they are more likely to be happy.” (CP11)
Theme 4: The need to promote the clinical role of community pharmacists
“In MUR we will find out whether or not the product is working, if we see that the product is not actually doing
what is supposed to do then we have to refer them back to the GP, it is not for us to say, we can’t make clinical
recommendations.” (CP16)
Theme 5: Professional identity
“We would like to have the funded COPD service back when we were actually caring for the patients before when
we were providing the COPD service….But you have to value the pharmacist time then, at the moment nobody is
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respiratory patients through such initiative, yet their state-
ment also reflected the extent of fragmentation in primary
care.
Lack of access to patients’ records
Furthermore, lack of access to patients’ clinical history
represented a challenge to provision of services, espe-
cially for new patients.
“If you are coming to me first time I know nothing
about you but if I had access to your clinical
history….it is easier for us to help you...” (CP3)
The need and acceptability of new technologies to
support respiratory patients
More than half of the interviewees perceived the adher-
ence level of their patients to be poor. Assessing adher-
ence level during consultations was reported to be
challenging. Eight CPs reported that they had to take the
patients’ word for it, while others (n = 9) assessed this by
looking through the patient medical records (PMRs) to
see the frequency of collecting inhalers as an indicator
of adherence.
“…it is difficult to know really. Obviously you can go
through it from the PMR and you can see the
frequency of dispensing....” (CP17)
“….you ask them about their adherence but what they
tell you whether it is true or not you do not know.
Most of the time they say they are pretty good, I mean
they admit one odd missed dose but usually they say
they take them regularly.” (CP1)
“… just from what they say and to see how often I get
prescriptions for the blue inhaler, if I know it has been
over prescribed then they are not using their preventer
often, and I just ask, there is no other real way to
assess adherence”. (CP9)
Patients’ inhaler technique was also reported to be
problematic by six CPs, who highlighted that there are
always errors in inhaler technique upon checking with
patients.
“…. each MUR we find there is something in the
technique that needs correction….” (CP6)
“….there are a lot of patients they can’t use these turbo
devices because it is just too difficult for them to make
the device work, whereas, the easier is the press device
but then likewise you get dexterity problems. Older
people can’t actually synchronise, they can’t press”.
(CP12)
“…there are quite a lot who make mistakes and who
don’t really know what they are doing which is why I
think they are targeting them as MUR subjects.”
(CP13)
Therefore, when INCATM technology was discussed as
an example with the interviewees, they were receptive
and open to the idea. The interviews highlighted no pre-use
of technology apart from YouTube videos for education.
“During MURs, I advise them to watch some videos on
Youtube. Otherwise, nothing related to technology” (CP11)
“No tools related to technology.” (CP15)
The analysis revealed certain pre-requisites as essential for
adopting any technological innovation, such as the INCATM
device. The five attributes of innovation mentioned by DOI
theory [29] were depicted in the CPs’ responses.
Relative advantage
The benefits perceived were related to the advantage of
the INCATM device in providing objective evidence
about the patient’s inhaler technique and adherence, in-
stead of trying to get this information from the patient,
which may not necessarily be accurate. The INCATM
technology was perceived as an easier way to monitor
patients and assess adherence, thus providing better and
more accurate service.
“It will be a bonus definitely, because if you can get
the results on adherence and technique…... Having the
results of that particular piece telling me that the
evidence level is this, then I can investigate why,
whereas now in the consultation room I will be
Table 3 additional quotations from respondents (Continued)
Theme/ Subtheme Respondents’ Quotations
valuing the pharmacist time. If I was providing all these services and not getting paid for it then there is no value
to my service yea, there is no value to my establishment, where I am going to get the money for to provide all
this, right?” (CP3)
“You can spend 10 min with the patient but you can’t spend half an hour unless it is properly funded you know
that’s the only thing, it is easier to spend 10 mins that’s fine but if you are going into a lot of details with the
patient then you need an extra funding to do all the extra services. It’s like an extra service, then we can spend
half an hour with the patient and go through all the queries and all the problems.” (CP21)
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spending time to find out about that adherence level
and still not get it right whereas with this I have
evidence.” (CP19)
Compatibility
The INCATM technology was perceived to be compatible
with the needs of CPs for novel ways that promotes patients’
understanding about inhaler technique and adherence.
“If it makes it easier for patients to understand, then
why not.” (CP 9)
However, the technology needs to be compatible with
time pressure and funding available for CPs.
“I think it is the way forward where we should be
developing the services and the advice we give and be
paid for it…..Well any new service you do you need to
be paid for it, you can’t just do it for free. It’s time,
isn’t it?” (CP20)
Complexity
CPs were willing to incorporate the INCATM technology
while supporting respiratory patients as long as it was
deemed to be safe and easy to use and not time consuming.
“As long-as it is easy to use, so patient friendly…”
(CP13)
Pharmacists proposed the need for proper training to
ensure ease of use.
“Yes, I will do it, but we need training” (CP5)
“Yea, as long as there is training, I like technology; I
have an interest in it.” (CP11)
Trialability and observability
Some CPs (n = 4) commented on the necessity of trying
the new technology on a few patients and if tangible
benefits were observed in terms of patients’ outcomes,
then they can apply it to the rest of the patients, which
in this case refers to the trialability and observability at-
tributes of an innovation.
“There is no harm in trying, if after at the first 10-15 pa-
tients does not seem there is any benefit then we can al-
ways revert back to just old kind of normal way ….” (CP9)
This highlights the positive attitude among the inter-
viewed CPs towards the proposed technology. The
responses were also reflective of the prerequisites de-
scribed in Rogers DOI theory [29] to facilitate the adop-
tion of an innovation.
The need to promote the clinical role of community
pharmacists
MUR service was found to be the main form of support to
respiratory patients. Interestingly, four CPs perceived that
MUR was mostly about checking medication usage with
no clinical input in it. One attributing the clinical input to
be only part of the full medication review which is a lo-
cally commissioned service rather than the MUR service.
“You check how they use their medication that’s all,
there is no clinical input or anything else, and it’s just
the usage, it is not review really”. (CP1)
Three CPs did not feel that a clinical role within MUR
provision is within their remit, while others (n = 3)
highlighted the need to develop such a clinical role to
improve patients’ outcomes.
“Yes (referring to discussing the condition treatment
during MUR), but we can’t get involved clinically
because it is not our remit that’s down to the
surgery…” (CP12)
“I think when we get it (the services) right, it definitely
improves the patient’s view of us as professionals…We
do have quite a lot of patient contact but we want to
make that a bit more clinical if we can….” (CP13)
The above quotes are particularly noteworthy since
they raise the question as to how CPs perceive their role;
particularly, the clinical aspects associated with this role.
Interestingly, the CP quoted below commented that
many of the tasks that are currently done by the CP,
such as inhaler technique or flu vaccination, can be done
by support staff if they are properly trained to back-up
the pharmacist. This was perceived as a way to create a
space/time for the CPs to develop their clinical role,
which was in their view restricted to stepping up and
down the treatment.
“There is a lot of stuff that can be done by support staff,
it does not have to be a pharmacist…… Is it inhaler
technique? Do you need a pharmacist to check the
inhaler technique or can use one of your support staff,
where the pharmacist has to intervene is when you are
looking at therapy and it is not working and then either
increase or decrease, it is the clinical aspect we need to
develop, our clinical role better. Flu jabs, why do you
need a pharmacist to do flu jab? Why can’t support staff
do it? If they are appropriately trained…” (CP20)
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Therefore, the perceived understanding of the CPs to
their role can impact the quality of services offered to
patients and their perceptions about the services.
Professional identity
An emerging theme from the data was related to CPs’
professional identity. Five CPs believed that the proper
management of respiratory patients, especially COPD, is
a neglected area. They perceived that this necessitates
having a separate service with a more dedicated time,
due to the high economic burden of COPD on the NHS.
Analysis revealed how CPs’ willingness to provide more
services was conditioned by remuneration, despite the
perceived need to promote the management of respira-
tory patients, especially high-risk ones. Nevertheless, the
conditioned remuneration was justified by three CPs in
the light of the potential benefits in reducing hospital
admissions.
“…if there are any ways of making this sort of thing
“COPD management” a part of mainstream
community pharmacy services that will be a lot easier
….This is more of a sort of an administrative and
reimbursement…” (CP23)
“I am sure the government will save money if they
included that in one of our services we get reimbursed
for…The money they save from hospital admissions
will be well worth it. I mean how many COPD
patients keep going into hospital and if we keep an eye
on them but get paid for it I will make the effort to,
you know, staying on the top of their treatments.
Incentives, I guess are always going to be financial in
some ways, isn’t it?” (CP10)
Interestingly, CPs were open to even upgrading the
current services to include INCATM technology if remu-
neration is available similar to services offered by other
HCPs.
“…we should have remuneration for it not just as part
of the service. GPs get paid for just measuring blood
pressure which should be really the job anyway…so it
is things like this, that mentality has come through
now to the pharmacists: if there is no money involved
they do not want to do, remuneration.” (CP8)
“If we get paid for it. It is brilliant. I would say it is an
enhanced service so if you want me to do that you got
to pay me to recruit the patients and also monitor the
patient, make sure they are compliant etc.…. it is got
to be some sort of incentives. At the moment you can
just give the inhaler out but if you want to see
improvements and see if they are compliant and you
want me to put a device on it (the inhaler) then I need
to monitor and I have to call the patient in.” (CP20)
Discussion
The findings generated in this study shed the light on
several issues that were found to be challenging and
problematic in terms of managing respiratory patients in
the community. Several barriers have been identified;
some of these were related to CPs, such as time, work-
load, lack of resources, lack of incentives, while others
were related to patients, such as patients’ health beliefs,
patients’ attitudes and lack of time. These are similar to
the barriers cited by CPs while supporting asthma pa-
tients in Australia [40].
Fragmented care and lack of communication among
HCPs in primary care were perceived by CPs to be nega-
tively affecting care provision. This echoes the findings
of previous research which showed that fragmented care
and lack of communication among HCPs were perceived
as a challenge among COPD patients, informal carers
and HCPs in four European countries [41, 42]. This is
further escalated by the fact that there is no clear role
for the CP in the COPD patient care pathway [43]. In
another research focusing on CPs’ experiences as service
providers in an implementation trial of a specialist
asthma service in Australia, CPs have identified collabor-
ation with GPs as a key challenge [44]. Poor integration
with other parts of the NHS has been identified in a re-
cent review by NHS England to be among the barriers
to better utilisation of the community pharmacy work-
force [45]. This, in return, stresses the importance of
tackling the problem of poor integration and communi-
cation between HCPs, as a way to enhancing care pro-
vided to patients.
In the current study, CPs did not clearly recognise
their clinical role within the MUR, and perceived a need
to promote this role, which highlights lack of recogni-
tion of inhaler technique as a clinical intervention
among CPs. For some CPs, the clinical role was re-
stricted to stepping treatment up and down for patients.
However, for respiratory patients, having correct inhaler
technique is pivotal for optimal drug delivery to the
lungs [46]. Errors in inhaler technique result in no drug
or a reduced amount of drug reaching the lungs [21, 47].
Consequently, rectifying inhaler technique is a purely
clinical aspect which can be done by the CP in an MUR.
Therefore, this raises an important question about the
CPs’ negative perception of the extent of their clinical
role. A previous research highlighted that hospital phar-
macists identified themselves more with the clinical
practitioner identity as compared to CPs [48]. Hospital
pharmacists defined clinical work as that undertaken at
the patient’s level which involves applying knowledge
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about medicines to a person’s condition. Even though
CPs described their role as spending time with patients
talking about symptoms and treatment, they did not ex-
plicitly refer to it as being ‘clinical’ [48].
CPs do not usually have full access to the clinical his-
tory of the patient and the Summary Care Record (SCR)
accessible to UK CPs may not contain adequate informa-
tion [45, 49]. This was highlighted as a limitation to ef-
fective service delivery for respiratory patients. The
importance of having full access to clinical information
has been previously emphasised [45, 50–52]. Similarly,
in a study interviewing CPs about their role in dementia
care in the UK, CPs echoed the lack of clinical role in
this area and attributed that to isolation, lack of access
to patients’ clinical records, poor integration into the
healthcare system and being viewed as shopkeepers
which provided a sense of inferiority [49]. This in return
provides a supportive explanation as to why CPs per-
ceived their clinical role to be lacking, since fragmenta-
tion of care and lack of access to patients’ clinical
records were raised as problematic issues. Furthermore,
a previous research in Scotland indicated that patients
with LTCs had more trust in the GP regarding their dis-
ease management, due to their access to the full medical
history, and were less likely to approach CPs, as the ser-
vices offered were perceived to be incomplete [53]. This
in return highlights the importance of granting CPs’ ac-
cess to the clinical records of patients. In fact, the rollout
of SCR into community pharmacies started in England
in mid-2015 and was expected to be completed by end
2017 [54, 55]. Despite that SCR do not include enough
information as highlighted earlier, yet CPs should recog-
nise this initiative as a potential opportunity to promote
the way they engage with patients and promote the clin-
ical aspects of the services they deliver. The recent up-
date as per May 2018 indicates that more than 93% of
community pharmacies have access to SCR and more
than 24,000 pharmacy professionals completed their
SCR e-learning [56]. Another approach which would also
enable CPs to embrace a greater clinical role [57–59]
would be pharmacy independent prescribing, which has
been introduced in the UK since 2006 [58, 60]. However,
the implementation of pharmacist prescribing is poor in
community pharmacy setting compared to other sectors,
such as hospital and primary care (GP surgeries) [57].
Whilst some barriers to independent prescribing are com-
mon across all pharmacy sectors, CPs face additional chal-
lenges [57, 58]. In the current study, none of the
respondents have reported to be qualified as an independ-
ent prescriber.
Poor adherence to inhaled therapy is directly associ-
ated with poor clinical outcomes and increased health-
care expenditure [13, 61, 62]. In fact, most participants
indicated that patients’ inhaler technique and adherence
were a challenge. This is well documented in the litera-
ture [9, 11, 13, 18]. Responses of CPs reflected positive
attitudes towards the INCATM technology and demon-
strated the need for such a technology as illustrated by
Rogers DOI theory [29] in terms of the attributes that
are essential for the adoption of new innovations. The
INCATM technology was perceived by CPs as an educa-
tional tool [20] that provides objective feedback on pa-
tients’ inhaler technique and adherence level in real-life
situations, compared to the subjective measures used
currently [10, 19, 20]. This technology can help CPs in
providing personalised advice that is tailored to patients’
needs during consultations, which can support the no-
tion of a clinical role within the MUR. Thus, the intro-
duction of assistive technologies such as the INCATM
technology can be of particular potential, given the poor
engagement and adherence to treatment reported among
respiratory patients in the literature [13]. The provision of
tailored education using quantitative feedback has been
associated with a higher magnitude of improvement in
comparison to the current best practice education [63].
Despite perceiving and advocating such potential oppor-
tunities, yet CPs willingness to provide new services or up-
grade existing services with technology was mainly driven
by finances (proper funding and correct re-imbursement).
Pertaining to this comes the dual professional/commercial
role of CPs, which has been a subject of continual discus-
sion [64] and their professional identity. The study of Elvey
et al. [48] showed that while pharmacists were trying to dis-
tance themselves from being viewed as shopkeepers, being
a business person was an important part of the identity due
to the satisfaction attained by having their own business
and autonomy. It is clear that although GP and pharmacy
services are commissioned in a similar fashion in the UK,
the work setting adds to the business perception of phar-
macy. Two qualitative studies in the UK [65, 66] reported
how the professional identity of CPs underpinned many of
the perceived barriers to provision of services to patients
with LTCs, including lack of remuneration and the retail
environment of community pharmacy.
Strengths and limitations
The current study provided an in-depth account into
CPs’ perceptions about current care and technology use
for supporting respiratory patients. To our knowledge,
few studies exist about CPs’ perceptions regarding the
use of technology for supporting patients with inhaler
technique and adherence. Data saturation was ensured
during data collection and all interviews were conducted
face-to-face. Despite of the fact that the CPs were ran-
domly approached, the selection bias might have oc-
curred, since participation is more likely to involve the
more motivated CPs or those with more interest in re-
spiratory conditions. Another limitation of the study is
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that perceptions were only explored among CPs owning
or working in independent community pharmacies, thus
limiting the generalisability of the results across the Eng-
lish community pharmacy sector.
Conclusion
The current study highlighted some factors affecting the
management of respiratory patients in community phar-
macies in London, such as fragmentation of primary
care and perceived lack of clinical role. Issues pertaining
to professional identity, notably remuneration, appeared
to be a major driver for willingness to offer new services
or promote existing services. The study also highlighted
some measures that can augment CPs’ practice while
managing respiratory patients, such as the use of tech-
nologies, for example the INCATM technology, to pro-
mote objective counselling to patients regarding inhaler
technique and adherence. The study also highlights the
need for clinical role recognition and facilitation through
accessibility to patients’ records to enable CPs to have a
more recognised role in respiratory patients’ care pathway.
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